Acertis Patent-Cliff Exposure & CMS Drug Spending Portfolio

Acertis (US): 3 reconciled FDA prescription therapies, $1.4M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$1.0M
2024 Medicaid Spend$325K
California HCAI SB 17 Filings4 WAC filings (max 43.8% 2-yr change)